VBI Vaccines Inc. (VBIVQ)

Market Cap	14.34K
Revenue (ttm)	9.41M
Net Income (ttm)	-83.99M
Shares Out	28.68M
EPS (ttm)	-4.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	48,521
Open	0.0005
Previous Close	0.0005
Day's Range	0.0005 - 0.0005
52-Week Range	0.0002 - 1.3500
Beta	2.05
RSI	33.35
Earnings Date	Mar 7, 2025

About VBI Vaccines

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jeffery Baxter
• Employees: 138
• Stock Exchange: OTCMKTS
• Ticker Symbol: VBIVQ

Financial Performance

In 2023, VBI Vaccines's revenue was $8.68 million, an increase of 702.40% compared to the previous year's $1.08 million. Losses were -$93.84 million, -17.18% less than in 2022.